Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Umbilical cord-derived mesenchymal stem cell(TricelX) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Umbilical cord-derived mesenchymal stem cell(TricelX): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP.
8 min read
GVV-858 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
GVV-858: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
EGEN-5784 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
EGEN-5784: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
CD33/CD123/CLL-1 CAR-T Cells(Hebei Taihe Chunyu Biotechnology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
CD33/CD123/CLL-1 CAR-T Cells(Hebei Taihe Chunyu Biotechnology): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical.
8 min read
BMS-986490 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
BMS-986490: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
CD7-specific CAR gene-engineered T cells(Shenzhen Geno-Immune Medical Institute) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
CD7-specific CAR gene-engineered T cells(Shenzhen Geno-Immune Medical Institute): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review.
8 min read
Human T Lymphoid Progenitor(Assistance Publique–Hôpitaux de Paris) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Human T Lymphoid Progenitor(Assistance Publique–Hôpitaux de Paris): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical.
8 min read
Respiratory Syncytial Virus Vaccine ( Ab&B Bio-Tech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Respiratory Syncytial Virus Vaccine ( Ab&B Bio-Tech): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP.
8 min read
Mixed activated killer (MAK) immune cells(Beijing Tuohua Weiye Biotechnology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Mixed activated killer (MAK) immune cells(Beijing Tuohua Weiye Biotechnology): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.
8 min read
Fecal microbiota(Fondazione Policlinico Universitario Agostino Gemelli IRCCS) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Fecal microbiota(Fondazione Policlinico Universitario Agostino Gemelli IRCCS): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.
8 min read
IDO-8 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
IDO-8: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
CB-AC-01 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
CB-AC-01: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.